AMS at a Glance
Advanced Medical Solutions Group plc is a leading developer and manufacturer of innovative and technologically advanced products for the global surgical and advanced woundcare markets.
Our primary focus is to create quality outcomes for our:
Full Year End31 December 2018
Interim Dividend Payment26 October 2018
Interim Dividend Record Date28 September 2018
Interim Results Announcement12 September 2018
Half Year End30 June 2018
Final Dividend Payment15 June 2018
Annual General Meeting6 June 2018
Preliminary Results Announcement14 March 2018
Latest Financial Highlights
AMS continues to progress as a leading international provider of high quality, high value, innovative and technologically advanced products for the surgical and advanced wound care markets. We are pleased to report another year of strong revenue growth, profit performance and cash generation.
Our revenues increased 16% to £96.9 million (2016: £83.2 million), representing growth of 12% on a constant currency basis and our adjusted profit before tax increased by 29% to £25.4 million (2016: £19.7 million) and our profit before tax increased by 32% to £25.3 million (2016: £19.1 million). The continued strong cash generation of the business has resulted in the Group ending the year with net cash of £62.5 million (2016: £51.1 million).
Good progress has been made with all of our brands. LiquiBand® continues to do well in the US and we have gained a further 2% market share since we last reported to make our market share by volume to 26%. Revenue from our RESORBA® brands grew steadily across all territories and has grown by 15% and by 6% at constant currency to £20.8 million (2016: £18.1 million), while ActivHeal® grew by 4% to £6.3 million (2016: £6.0 million).
We were pleased to announce in October 2017 that we had agreed a patent out-licensing agreement with Organogenisis for a collagen based wound dressing containing Polyhexamethylene Biguanide (“PHMB”). Under this agreement, we receive royalties from Organogenesis’ net sales in the US on the product. The agreement is in place for the life of the patent which expires in October 2026.
AMS continues to be in robust financial health and we are continuing to grow our international footprint and scale. The Group is well positioned to increase investment in internal innovation and to actively pursue external opportunities in line with our long-term strategy and growth objectives.